Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...

Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

While Amgen’s third-quarter financial results on Wednesday were “somewhat uneventful,” investors continue to be focused on ...

I'd advise readers to pay close attention to these products' performance ... This is an optimistic or “best case” scenario, and it is clear that Amgen will need support from its pipeline ...

Some of the top performers included the osteoporosis ... the significant opportunities ahead. Beyond the products currently on the market, Amgen benefits from a pipeline of multiple-drug ...